Activating mutations in the RET proto-oncogene are central to the development of MTC in almost all patients with a hereditary form of the disease (germline, 95–98%), and in 45−50% of those with sporadic disease (somatic) (25, 26). The gene discussed is RET; the disease is medullary thyroid gland carcinoma.